Matthew Plavan
2010 - Cesca Therapeutics
In 2010, Matthew Plavan earned a total compensation of $408K as Chief Executive Officer & Chief Financial Officer at Cesca Therapeutics, a 7% increase compared to previous year.
Compensation breakdown
| Option Awards | $110,000 |
|---|---|
| Salary | $298,000 |
| Total | $408,000 |
Plavan received $298K in salary, accounting for 73% of the total pay in 2010.
Plavan also received $110K in option awards.
Rankings
In 2010, Matthew Plavan's compensation ranked 8,332nd out of 10,439 executives tracked by ExecPay. In other words, Plavan earned more than 20.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,332 out of 10,439 | 20th |
Division Manufacturing | 3,105 out of 3,838 | 19th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 500 out of 672 | 26th |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 163 out of 225 | 28th |
Industry Laboratory Apparatus and Furniture | 5 out of 11 | 55th |
Source: SEC filing on October 23, 2012.
Plavan's colleagues
We found four more compensation records of executives who worked with Matthew Plavan at Cesca Therapeutics in 2010.
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019